钆塞酸二钠增强磁共振成像与超声在肝细胞癌筛查中的成本效益分析

陈琪萍; 林苏; 史震山; 朱月永; 李友炳

doi:10.3969/j.issn.1001-5256.2018.09.018

钆塞酸二钠增强磁共振成像与超声在肝细胞癌筛查中的成本效益分析

DOI: 10.3969/j.issn.1001-5256.2018.09.018

1. 福建医科大学附属第一医院肝病中心
2. 福建医科大学附属第一医院影像科

基金项目:

福建省自然科学基金项目(2016Y0039,2015Y0057)；

详细信息

中图分类号: R735.7;R445
计量
- 文章访问数: 2179
- HTML全文浏览量: 39
- PDF下载量: 342
- 被引次数: 0
出版历程
- 收稿日期: 2018-03-05
- 出版日期: 2018-09-20

A cost-effectiveness analysis of Gd-EOB-DTPA contrast-enhanced magnetic resonance imaging versus ultrasound in hepatocellular carcinoma screening

Liver Research Center, The First Affiliated Hospital of Fujian Medical University

Research funding:

摘要

摘要: 目的比较在肝癌高危人群中采用钆塞酸二钠增强MRI(EMRI)与超声行肝癌筛查的成本效益比。方法应用Tree Age Pro 2011软件建立决策树模型,采用数学模型模拟肝硬化患者每6个月行EMRI或超声筛查的成本与收益,计算不同筛查模式下的成本效益比。结果 EMRI组和超声组平均每人每次用于肝癌筛查的成本分别为2050.2元和262.6元,获得效益分别为0.11生命年(YLG)和0.02 YLG。当肝癌发病率为17.8%时,EMRI组与超声组的成本效益比大致相同,每1个YLG的成本大致均为11445元,肝癌发病率越高,EMRI检查成本越低,筛查效果越好。EMRI价格越低,其成本效益比逐渐下降,筛查效果越明显。结论肝癌筛查的成本效益与肝癌发病率及检查价格密切相关。当肝癌风险高于17.8%时,采用EMRI筛查可获得较好的成本效益比。
- 癌,肝细胞 /
- 磁共振成像 /
- 超声检查 /
- 早期诊断 /
- 费用效益分析
Abstract: Objective To investigate the cost-effectiveness ratio of Gd-EOB-DTPA contrast-enhanced magnetic resonance imaging (EMRI) versus ultrasound in liver cancer screening for the high-risk population. Methods The Tree Age Pro 2011 software was used to establish a decision-tree model. A mathematical model was used to simulate the costs and benefits of EMRI or ultrasound screening every 6 months in patients with liver cirrhosis, and the cost-effectiveness ratios under different screening models were calculated. Results The EMRI group had a mean cost of liver cancer screening of 2050. 2 RMB each person each time and mean benefits of 0. 11 YLG, while the ultrasound group had a mean cost of 262. 6 RMB and mean benefits of 0. 02 YLG. When the incidence rate of liver cancer was 17. 8%, the EMRI group had a similar cost-effectiveness ratio as the ultrasound group, and the cost of 1 YLG was 11445 RMB; EMRI tended to have a lower cost and a better effect in screening with the increase in the incidence rate of liver cancer. The cost-effectiveness ratio of EMRI gradually decreased with the reduction in its price, and its effect in screening gradually increased with the reduction in price. Conclusion The cost-effectiveness of liver cancer screening is closely related to the incidence rate of liver cancer and the price of screening. EMRI has a good cost-effectiveness ratio in screening when the risk of liver cancer is higher than 17. 8%.
- carcinoma, hepatocellular /
- magnetic resonance imaging /
- ultrasonography /
- early diagnosis /
- cost-benefit analysis

HTML全文

参考文献(22)

[1]FITZMAURICE C, DICKER D, PAIN A, et al.The global burden of cancer 2013[J].JAMA Oncol, 2015, 1 (4) :505-527.

[2]CHEN JG.Trends in the incidence of liver cancer and its primary prevention in China[J].J Clin Hepatol, 2012, 28 (4) :256-260. (in Chinese) 陈建国.中国肝癌发病趋势和一级预防[J].临床肝胆病杂志, 2012, 28 (4) :256-260.

[3]ZUO TT, ZHENG RS, ZHANG SW, et al.Incidence and mortality of liver cancer in China in 2011[J].Chin J Cancer, 2015, 34 (11) :508-513.

[4]WANG R, CHEN XZ, ZHANG MG, et al.Incidence and mortality of liver cancer in mainland China:Changes in first decade of 21st century[J].Hepatogastroenterology, 2015, 62 (137) :118-121.

[5]ZUO TT, ZHENG RS, ZENG HM, et al.Analysis of liver cancer incidence and trend in China[J].Chin J Oncol, 2015, 37 (9) :691-696. (in Chinese) 左婷婷, 郑荣寿, 曾红梅, 等.中国肝癌发病状况与趋势分析[J].中华肿瘤杂志, 2015, 37 (9) :691-696.

[6]EL-SERAG HB.Hepatocellular carcinoma[J].N Engl J Med, 2011, 365 (12) :1118-1127.

[7]FORNER A, LLOVET JM, BRUIX J.Hepatocellular carcinoma[J].Lancet, 2012, 379 (9822) :1245-1255.

[8]ALLEMANI C, WEIR HK, CARREIRA H, et al.Global surveillance of cancer survival 1995-2009:Analysis of individual data for25, 676, 887 patients from 279 population-based registries in 67countries (CONCORD-2) [J].Lancet, 2015, 385 (9972) :977-1010.

[9]BRUIX J, SHERMAN M.Management of hepatocellular carcinoma:An update[J].Hepatology, 2011, 53 (3) :1020-1022.

[10]SINGAL A, VOLK ML, WALJEE A, et al.Meta-analysis:Surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis[J].Aliment Pharmacol Ther, 2009, 30 (1) :37-47.

[11]YU NC, CHAUDHARI V, RAMAN SS, et al.CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis[J].Clin Gastroenterol Hepatol, 2011, 9 (2) :161-167.

[12]ZHANG CY, FU Y, LI XD, et al.Advances in imaging diagnosis of liver cancer[J].J Clin Hepatol, 2017, 33 (7) :1266-1269. (in Chinese) 张春雨, 付宇, 李晓东, 等.肝癌的影像学诊断进展[J].临床肝胆病杂志, 2017, 33 (7) :1266-1269.

[13]KIM HD, LIM YS, HAN S, et al.Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival[J].Gastroenterology, 2015, 148 (7) :1371-1382.

[14]KIM SY, AN J, LIM YS, et al.MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma[J].JAMA Oncol, 2017, 3:456-463.

[15]WANG JH, CHANGCHIEN CS, HU TH, et al.The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma-survival analysis of 3892 patients[J].Eur JCancer, 2008, 44 (7) :1000-1006.

[16]KAO WY, CHAO Y, CHANG CC, et al.Prognosis of early-stage hepatocellular carcinoma:The clinical implications of substages of Barcelona clinic liver cancer system based on a cohort of 1265 patients[J].Medicine (Baltimore) , 2015, 94 (43) :1929.

[17]VEL ZQUEZ RF, RODR GUEZ M, NAVASCU S CA, et al.Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis[J].Hepatology, 2003, 38 (4) :520-527.

[18]FATTOVICH G, STROFFOLINI T, ZAGNI I, et al.Hepatocellular carcinoma in cirrhosis:Incidence and risk factors[J].Gastroenterology, 2004, 127 (1) :35-50.

[19]KUPER H, YE W, BROOM U, et al.The risk of liver and bile duct cancer in patients with chronic viral hepatitis, alcoholism, or cirrhosis[J].Hepatology, 2001, 34 (4) :714-718.

[20]GOOSSENS N, NAKAGAWA S, SUN X, et al.Cancer biomarker discovery and validation[J].Transl Cancer Res, 2015, 4 (3) :256-269.

[21]SORENSEN HT, FRIIS S, OLSEN JH, et al.Risk of liver and other types of cancer in patients with cirrhosis:A nationwide cohort study in Denmark[J].Hepatology, 1998, 28 (4) :921-925.

[22]LI P, DING HG, XU H, et al.Shortening liver cancer screening interval may improve the prognosis of patients with hepatitis B cirrhosis-related hepatocellular carcinoma[J].J Clin Hepatol, 2017, 33 (7) :1301-1304. (in Chinese) 李鹏, 丁惠国, 徐辉, 等.缩短肝癌筛查间隔对乙型肝炎肝硬化相关肝细胞癌患者预后的影响[J].临床肝胆病杂志, 2017, 33 (7) :1301-1304.

施引文献

资源附件(0)

访问统计